BioSpace News Archive

Curis, Inc. today announced that the first mesothelioma patient has been enrolled and dosed in the Phase I study of CA-170.

Medicenna Therapeutics Corp. today announced two presentations at the Immuno-Oncology 360° Conference to be held February 6-8, 2019 at the Crowne Plaza Times Square, New York NY.

Titan Pharmaceuticals, Inc. announced today that it has filed an amendment to its certificate of incorporation that will effect a 1-for-6 reverse stock split of the company’s issued and outstanding shares of common stock, warrants and options, which was approved by the company’s stockholders at a special meeting held on January 23, 2019.

Concert Pharmaceuticals, Inc. today announced that it has initiated the second Phase 1 clinical trial with CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia.

Pharmacies had combined revenue of approximately $6 million in fiscal year 2018 and are cash flow positive*

J. Kevin Buchi Assumes Chairmanship Role and Industry Experts Marc Kozin and Anna Protopapas Join Dicerna Board

Can-Fite BioPharma Ltd. announced that Pnina Fishman, Chief Executive Officer of Can-Fite Biopharma, has issued a Letter to Shareholders, the full text of which follows below.

New Insight from 9,000 AKI Patients Receiving Outpatient Dialysis Treatment; Large Collection of AKI Data is International First and Aims to Spur Further Investigation [24-January-2019] WALTHAM, Mass. , Jan. 24, 2019 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA), the nation’s leading renal care company, announces preliminary results from an analysis o

Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2018 financial results conference call and webcast for 8:00 a.m. ET on Thursday, February 14, 2019.

A breakthrough, fully disposable sternal plating system